Company profile
Merck & Co.
Diversified pharma
Share price · MRK
$135.17+22.61 (+20.09%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(35 total)
35Total Assets
15Approved
12Phase 3 / Filed
8Phase 1–2 / Early
13Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Doravirine(Pifeltro) | Approved | HIV reverse transcriptaseSmall molecule | HIVAtherosclerotic Cardiovascular Disease |
ensifentrine(Ohtuvayre) | Approved | PDE3/PDE4Small molecule | Chronic Obstructive Pulmonary Disease |
Ertugliflozin(Steglatro) | Approved | SGLT2Small molecule | Type 2 Diabetes |
Finerenone(Kerendia) | Approved | Mineralocorticoid receptorSmall molecule | Heart FailureChronic Kidney Disease |
| Approved | CTLA-4Monoclonal antibody | Non-Small Cell Lung Cancer | |
Ipragliflozin(Suglat) | Approved | SGLT2Small molecule | Type 2 Diabetes |
metformin(Glucophage) | Approved | AMPKSmall molecule | Type 2 Diabetes |
mometasone furoate/formoterol fumarate(Dulera / Zenhale) | Approved | Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptorSmall molecule | Asthma |
| Approved | PARPSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-1Small molecule | Non-Small Cell Lung Cancer | |
Raltegravir(Isentress) | Approved | HIV integraseSmall molecule | HIVAtherosclerotic Cardiovascular Disease |
Sitagliptin(Januvia) | Approved | DPP-4Small molecule | Type 2 Diabetes |
Sotatercept(Winrevair) | Approved | Activin receptor type IIA (ActRIIA)Protein / enzyme therapeutic | HypertensionHeart FailureNon-Small Cell Lung Cancer |
Vericiguat(Verquvo) | Approved | Soluble guanylate cyclaseSmall molecule | Heart Failure |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.